Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 44, Issue 7, Pages 1894-1899Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.44.7.1894-1899.2000
Keywords
-
Categories
Ask authors/readers for more resources
MICs, time-kills, and postantibiotic effects (PAEs) of ABT-773 (a new ketolide) and 10 other agents were determined against 226 pneumococci. Against 78 ermB- and 44 mefE-containing strains, ABT-773 MICs at which 50% of the isolates tested were inhibited (MIC(50)s) and MIC(90)s were 0.016 to 0.03 and 0.125 mu g/ml, respectively. Clindamycin was active only against macrolide-resistant strains containing mefE (MIC50, 0.06 mu g/ml; MIC90, 0.125 mu g/ml). Activities of pristinamycin (MIC90 0.5 mu g/ml) and vancomycin (MIC90 0.25 mu g/ml) were unaffected by macrolide or penicillin resistance, while beta-lactam MICs rose with those of penicillin G. Against 19 strains with L4 ribosomal protein mutations and two strains with mutations in domain V of 23S rRNA, ABT-773 MICs were 0.03 to 0.25 mu g/ml, while macrolide and azalide MICs were all greater than or equal to 16.0 mu g/ml. ABT-773 was bactericidal at twice the MIC after 24 h for 8 of 12 strains (including three strains with erythromycin MICs greater than or equal to 64.0 mu g/ml). Kill kinetics of erythromycin, azithromycin, clarithromycin, and roxithromycin against macrolide-susceptible strains were slower than those of ABT-773. ABT-773 had longer PAEs than macrolides, azithromycin, clindamycin, or beta-lactams, including against ermB-containing strains. ABT-773, therefore, shows promising in vitro activity against macrolide-susceptible as well as -resistant pneumococci.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available